Discussion on the Power of RWE in Drug Development and Market Access

Aetion invited two leaders in real world evidence (RWE) to share their thoughts on industry trends. Chief Data Science Officer of Janssen Research and Development Najat Khan and Head of RWE at Sanofi Bob LoCasale provided insight and advice for others seeking to incorporate RWE into their decision-making processes. Dr. Khan noted that the use of RWE has expanded substantially since the beginning of the COVID-19 pandemic.

Dr. LoCasale remarked, “RWE, for me, is about patient-generated data, and uncovering the heterogeneity within patient populations to generate insights on groups beyond homogenous clinical trial populations. The power of RWE is clear for me in that space, and we can achieve it by enhancing our data input.” Read more here.

(Source: Aetion, 5/13/21)